Targeting pancreatic cancer with Allogeneic Off-the-Shelf PSCA-CAR NK cells
Grant Award Details
Grant Type:
Grant Number:
TRAN1-16192
Investigator(s):
Award Value:
$6,036,000
Status:
Pre-Active
Grant Application Details
Application Title:
Targeting pancreatic cancer with Allogeneic Off-the-Shelf PSCA-CAR NK cells
Public Abstract:
Translational Candidate
PSCA-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells
Area of Impact
patients with metastatic pancreatic cancer or other cancers that also highly express PSCA
Mechanism of Action
PSCA-CAR_sIL15 NK cells are umbilical cord blood-derived CD34+ HSCs that are engineered to target PSCA and express soluble IL-15, and then are differentiated into NK cells. The cells can target PSCA postive tumor cells and the IL15 secreted by PSCA-CAR_sIL15 can activate T cells and NK cells in the tumor microenvironment.
Unmet Medical Need
Pancreatic cancer (PC) is highly lethal, with a 5-year overall survival rate of 9%, and is the third leading cause of cancer-related death after lung and colon cancer. Pancreatic cancer disproportionately affects Black Americans. Successful translation of our safe, “off-the-shelf” cellular therapy of PSCA-CAR_sIL15 NK cells will diminish the life-threatening clinical manifestations of metastatic PC patients.
Project Objective
Complete Pre-IND submission and finalize IND plans
Major Proposed Activities
PSCA-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells
Area of Impact
patients with metastatic pancreatic cancer or other cancers that also highly express PSCA
Mechanism of Action
PSCA-CAR_sIL15 NK cells are umbilical cord blood-derived CD34+ HSCs that are engineered to target PSCA and express soluble IL-15, and then are differentiated into NK cells. The cells can target PSCA postive tumor cells and the IL15 secreted by PSCA-CAR_sIL15 can activate T cells and NK cells in the tumor microenvironment.
Unmet Medical Need
Pancreatic cancer (PC) is highly lethal, with a 5-year overall survival rate of 9%, and is the third leading cause of cancer-related death after lung and colon cancer. Pancreatic cancer disproportionately affects Black Americans. Successful translation of our safe, “off-the-shelf” cellular therapy of PSCA-CAR_sIL15 NK cells will diminish the life-threatening clinical manifestations of metastatic PC patients.
Project Objective
Complete Pre-IND submission and finalize IND plans
Major Proposed Activities
- Manufacture PSCA-CAR_sIL15 NK cells and PK/PD study
- Pharmacology toxicity and optimize treatment schedule of PSCA-CAR_sIL15 NK cells in efficacy testing
- Confirm efficacy of PSCA-CAR_sIL15 NK cells under optimized and safe conditions and Pre-IND submission
Statement of Benefit to California:
Pancreatic cancer (PC) is highly lethal, with a 5-year overall survival rate of 9%, and is the third leading cause of cancer-related death after lung and colon cancer. Pancreatic cancer disproportionately affects Black Americans. Successful translation of our safe, “off-the-shelf” cellular therapy of PSCA-CAR_sIL15 NK cells will diminish the life-threatening clinical manifestations of metastatic PC patients.